title: Update on reverse transcriptase inhibitors in HIV disease.
authors.affiliation: Centre for Immunology, St. Vincent's Hospital, Sydney, Australia.
authors.forename: A
authors.initials: A
authors.lastname: Carr
authors.forename: M
authors.initials: M
authors.lastname: Loewenthal
authors.forename: D A
authors.initials: DA
authors.lastname: Cooper
mesh_terms: D000163:Acquired Immunodeficiency Syndrome / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D016049:Didanosine / Q000008:administration & dosage* / Q000009:adverse effects; D006801:Humans; D011379:Prognosis; D018894:Reverse Transcriptase Inhibitors; D012307:Risk Factors; D016047:Zalcitabine / Q000008:administration & dosage* / Q000009:adverse effects; D015215:Zidovudine / Q000008:administration & dosage* / Q000009:adverse effects
chemical_list: D018894:Reverse Transcriptase Inhibitors; D015215:Zidovudine; D016047:Zalcitabine; D016049:Didanosine